Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Nebraska Certifies Ballot Measures to Legalize Medical Cannabis

Efforts to legalize medical cannabis in Nebraska have officially been approved for the November election, despite a lawsuit and a statewide review of the validity of collected signatures.

Bob Evnen, the secretary of state, announced on Sept. 14, 2024, that the group Nebraskans for Medical Marijuana had gathered an estimated 90,000 legitimate signatures. The announcement was made precisely one year from receiving the signature initiative’s third effort in 2023, which coincided with the finalization of the November 5 ballot.

Evnen mentioned that the procedure for gathering signatures had sparked questions, which the office of Attorney General Mike Hilgers was looking into. One person so far who participated in obtaining signatures faces felony charges as part of the investigation.

Crista Eggers, statewide campaign manager for the medical marijuana proposal, thanked Hilgers and municipal leaders for maintaining openness throughout the petition process. She expressed gratitude to officials for resolving any differences and maintaining the credibility of the public initiative process.

One of the measures — the Nebraska Medical Marijuana Regulation Act — aims to legalize the possession, production, distribution and sale of marijuana for medical use. It also proposes creating the Nebraska Medical Marijuana Commission, which would be responsible for regulating cannabis in the state. If the legislation passes, the commission would be required to establish guidelines for approving or rejecting applications from marijuana-related businesses by July next year, with the first licenses being issued by October 2025.

The second measure — the Nebraska Medical Marijuana Patient Protection Act — seeks to authorize patients to possess a maximum of five ounces of medical marijuana. This measure would also exempt caregivers from legal consequences for helping patients use marijuana and require written recommendations from healthcare providers. For minors, this recommendation would also need to come from a parent or legal guardian.

State law mandates that initiative petitions have valid signatures from at least 7% of Nebraska’s 86,500 registered voters, with at least 5% of the voters in 38 of the 93 counties in the state. Nearly 90,000 of the 114,000 signatures that the campaign presented in July were validated, surpassing the 5% level that was necessary in 52 counties.

However, the campaign is currently facing a legal challenge filed by John Kuehn, a rancher and veterinarian from Heartwell, who previously served in the state legislature. Kuehn claims that Evnen’s office has not provided access to the petition pages as requested under a public records law. He is seeking an independent review of those signatures and has asked the Lancaster County District Court to stop the measures from going before voters or stop the state from certifying any resultant polls results.

Kuehn’s lawsuit also argues that the campaign did not gather enough legitimate signatures and that the proposed measures represent an unconstitutional transfer of regulatory power from the Legislature. Furthermore, the lawsuit challenges the initiatives, stating that cannabis’ classification as a schedule 1 substance under federal law prevents the measures from being enacted.

Cannabis enterprises such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) may regard some of the arguments in the lawsuit to be far-fetched, given that several states have legalized medical and even recreational marijuana despite its current federal classification.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Nebraska Lawsuit Aims to Void State’s Medical Cannabis Ballot Measures

A former Nebraska senator and past member of the Nebraska Health Board has filed a lawsuit aimed at stopping two state medical marijuana ballot petitions. John Kuehn, a rancher and veterinarian from Heartwell, is challenging the placement of these measures on the Nov. 5 , 2024, ballot.

Kuehn has listed seven key reasons for his challenge, including claims of procedural violations and constitutional issues under federal and state laws. Kuehn’s legal team, led by attorneys Cameron E. Guenzel, Steven E. Guenzel and Andrew La Grone (another former state senator), filed the case in Lancaster County District Court. The lawsuit seeks to prevent Bob Evnen, the secretary of state of Nebraska, from approving the two petitions for the ballot. Further, Kuehn wishes to prevent the state from recognizing the election results even if these measures are approved.

The two measures in question would legalize medical marijuana and outline who would be considered a patient, provider and caregiver. The measures are supported by Nebraskans for Medical Cannabis, with leaders including campaign manager Crista Eggers, State Senator Anna Wishart and former State Senator Adam Morfeld. Kuehn’s lawsuit names these campaign leaders as well as Evnen.

Kuehn claims that there were several issues with the petitions, including delays in accessing the signatures, a lack of valid signatures, duplicate entries and an invalid sponsor statement from Wishart. He also argues that the petitions violate the state’s constitutional single-subject rule, unlawfully delegate power to a proposed Nebraska Medical Marijuana Commission and conflict with federal laws banning cannabis as a Schedule 1 substance. The lawsuit further asserts that most signatures were collected either before the official petition circulation period or after the deadline. Kuehn argues that invalid signatures were unlawfully accepted by the secretary of state’s office. However, the lawsuit doesn’t specify exactly how many signatures may be invalid.

Mike Hilgers, the state’s attorney general, announced a press conference to address alleged falsifications in the petition process, though it is unclear if these remarks relate to the medical marijuana measures.

This is not the first attempt for Nebraska to place medical cannabis on the ballot, as previous efforts in 2020 and 2022 fell short due to similar legal challenges. The current campaign marks the group’s third attempt, and group officials are hopeful that this will be their final push. However, the lawsuit presents significant hurdles that could delay or derail their efforts once again.

The cannabis industry, including established enterprises such as SNDL Inc. (NASDAQ: SNDL), will likely be watching how the legal battle pans out and whether voters will finally cast their ballots on this matter as the year draws to an end.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations

Lexaria, a global innovator in drug delivery platforms, announced the appointment of Richard Christopher as its new CEO, replacing Chris Bunka who will serve in his new capacity as Executive Strategic Advisor while remaining Chairman of the Board
Lexaria also announced entering a Material Transfer Agreement with an undisclosed pharmaceutical industry partner, leading to speculation of which company has taken this formal step to get closer to Lexaria’s technology
The company is focusing on this pharmaceutical industry collaboration and on investigations in cardiometabolic and GLP-1 sectors (alternative diabetes and obesity treatments), a huge sector that particularly needs its unmatched technology
The company seems one step closer to exploiting commercial opportunities in the sector, with a goal toward associated commercialization of its patented DehydraTECH technology

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, has, since 2016, worked on the development of its patented DehydraTECH(TM) technology. It has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. These efforts have earned it 46 patents in the United States, European Union and other countries, with many more pending worldwide (https://cnw.fm/mBfkA).

With the success achieved thus far, Lexaria is looking to pivot and focus on pharmaceutical industry collaboration and operations. To help steer it in the right direction, the company appointed Richard Christopher as its new CEO, effective Aug. 31, 2024. He will replace Chris Bunka, who will serve in his new capacity as Executive Strategic Advisor to the management team. He will continue to support and advise Lexaria and remain chairman of the board of directors.

“I’m delighted that I have been appointed to lead Lexaria,” noted Mr. Christopher. “The company is well positioned for an exciting period of growth centered around the advancement and improvement of drug delivery in the GLP-1 marketplace. We are preparing for an active and collaborative new era for Lexaria in the pharmaceutical industry,” he added (https://cnw.fm/kj2tz).

Mr. Christopher will lend his vast experience spanning more than three decades in the medical device and pharmaceutical industries. He also has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning, and capital markets. Most recently, he was the Chief Financial Officer at InVivo Therapeutics, a research and clinical-stage biomaterials and biotechnology company focusing on treating spinal cord injuries.

This appointment directly followed the Material Transfer Agreement with a pharmaceutical company (“PharmaCO”) to evaluate Lexaria’s DehydraTECH technology in a pre-clinical setting. Under the terms of the agreement, Lexaria will formulate and supply certain DehydraTECH compositions for use in animal studies. PharmaCo has been awarded a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under examination, and the project should be completed within roughly six months or less (https://cnw.fm/62ydz).

Lexaria is looking to double down on its DehydraTECH research and commercialization. This move points to this commitment and ushers in a new chapter for the company. Its management is optimistic about the future, not just from a commercial standpoint and creating shareholder value, but also by positively transforming human health.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds Cannabis Grown in Colombian Jungles Possesses Uncommon Terpenes

A new study on cannabis grown in Colombia highlights the impressive variety of phytochemicals in the plants. The study identified four different chemotypes based on their cannabinoid profiles, revealing an abundance of uncommon terpenes.

The study’s results, which were published in the “Phytochemical Analysis” journal, indicate that the wide range of compounds found in Colombian marijuana could benefit both growers and the medical cannabis industry. Further, the findings demonstrate Colombia’s potential to be a leader in the global cannabis industry, particularly in South America, as new markets continue to develop.

The authors state that one reason for this diversity is Colombia’s varied environmental regions. The country is known for its array of landscapes, including snowy mountains, tropical coastlines, deserts, rainforests and grasslands. This environmental variety has already contributed to the success of other agricultural industries, such as coffee production.

Researchers collected 156 cannabis samples from 17 licensed medical cannabis cultivation sites, spanning 7 provinces and 5 regions of Colombia. Growers provided information about the types of plants used in the samples — local, imported or hybrids — as well as specifics regarding the growth conditions (indoor, outdoor or greenhouse).

Significant structural and color differences were evident in the samples even before any chemical testing was conducted. The study found that whereas some blooms were more open and airy, others were compact and dense. The samples’ colors ranged from bright, warm tones to softer, more subdued hues.

The research team divided the cannabis into four primary categories after examining the cannabinoids in each sample: type 1, which was dominant in THC; type 3, which was prominent in CBD; type 4, which was dominant in CBG; and type 2, which was balanced. Even though these kinds were distributed throughout Colombia, certain regional patterns did show up.

For instance, plants from the Coffee Triangle region had the highest concentrations of CBD-A, whereas cannabis from the Amazon and south-central regions had the highest THC-A levels. Additionally, the researchers found that cannabis from these same regions contained higher levels of certain compounds, such as CBDV, CBGA and THCV.

The authors also measured the levels of 23 distinct terpenes in the samples. THC-dominant strains showed the greatest variety of terpenes, while CBD-dominant and balanced strains had β-myrcene as the most common terpene. Some types also contained high levels of terpenes that are less common in North American cannabis, such as nerolidol and linalool. The study highlights that the observed diversity in these samples is likely due to a combination of genetic factors and the environment in which the plants were grown.

Interestingly, the research found that nearly one-half of the samples were local varieties, with most of the rest being hybrids of imported and local strains. Very few samples were purely imported. This suggests that Colombia’s long history of growing cannabis before legalization has influenced the country’s current medical cannabis market, with growers blending local and foreign cultivars.

The study provides the first detailed metabolic analysis of legally grown cannabis in Colombia, uncovering significant chemical diversity. The researchers believe that this diversity could contribute to new opportunities in medical cannabis worldwide. They recommend further studies that include full-genome sequencing and a deeper exploration of how environmental factors influence the chemical makeup of cannabis plants.

As more cannabis companies and patients leverage these different cannabis compounds for therapeutic purposes and their efficacy is confirmed, the cannabis industry could boom even more, and ancillary entities such as Innovative Industrial Properties Inc. (NYSE: IIPR) could also see a commensurate uptick in the business opportunities available to them.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trump Backs Ongoing State, Federal Cannabis Reforms

Donald Trump reaffirmed his support for legalizing recreational cannabis in Florida earlier this week. He also expressed his approval for rescheduling marijuana at the federal level and advocated for removing banking restrictions on state-licensed cannabis businesses.

While he hasn’t endorsed ending the federal ban on marijuana, U.S. presidential candidate Donald Trump has made comments that suggest he’s aware of its potential political influence. His remarks came just ahead of his first debate with Vice President Kamala Harris.

Trump’s support for Amendment 3, which he first hinted at in August, could potentially boost the initiative. If passed, the amendment would allow recreational sales and permit adults aged 21 years of age and older to legally possess up to three ounces of cannabis. The amendment requires 60% voter approval to pass. Polls before Trump’s endorsement suggested it wasn’t certain whether the measure would hit this mark. If successful, Florida would become the 25th state to legalize recreational cannabis.

In addition to endorsing the Florida initiative, Trump expressed support for the Biden administration’s proposal to reclassify cannabis from schedule 1 to 3 under the Controlled Substances Act. Trump commented that this change would help advance research into the medical benefits of marijuana.

Reclassifying cannabis would eliminate some hurdles for medical research and provide financial relief to the marijuana industry. Currently, businesses involved in cannabis cannot claim typical business expenses when filing federal taxes because marijuana is classified under schedule 1. However, this reclassification would not make marijuana legal federally nor would it authorize its use as a prescription drug without specific regulatory approval.

While some uncertainty previously existed about how Trump would approach marijuana in a potential second term, he has shown signs of evolving on this issue. During his previous campaign, he stated that states should have the right to legalize marijuana but also criticized the negative impacts of such policies.

Notably, his administration took steps that contradicted his stance, such as rescinding a memo protecting state-licensed cannabis suppliers and proposing to remove a spending rider preventing federal interference with state medical cannabis programs.

Trump also emphasized his desire to collaborate with Congress to create sensible laws, including securing banking options for state-licensed cannabis businesses. Many financial institutions currently avoid dealing with the marijuana industry due to fear of severe legal consequences, which has left marijuana companies heavily reliant on cash and vulnerable to robbery.

Although legislation to protect banks working with marijuana businesses has faced obstacles in Congress, Trump’s support could potentially push it forward if he were elected.

His evolving position on cannabis legalization may appeal to a broad spectrum of voters. Recent polls indicate that 70% of U.S. adults, including majorities across both political parties, believe cannabis should be legalized.

Trump’s evolving stance on cannabis reform, while not as far-reaching as complete federal legalization, may still have significant implications for his political strategy. What the cannabis industry and enterprises such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) hope for is for tangle reforms to be made at the federal level so that the growth of the industry can face fewer hurdles.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Clarifying Congress’ Intent on THC Could Help in Reforming Marijuana Laws

Back in 2018 when Congress passed the current farm bill that legalized hemp, Congress seemed to have been under the belief that hemp was for making rope rather than intoxicating products. However, the current debate around hemp is almost solely rotating around intoxicants.

It has become abundantly clear that the law passed in 2018, in a way, spawned the current proliferation of derivatives, including THC products. There is a heated debate, with people on either side making arguments in support of their positions. For example, the hemp industry wants the current law to remain as it is, leaving makers of hemp-derived THC intoxicants to operate in the current legal gray area. They claim that the phrasing “all derivatives” opened the gate to THC products from hemp and the status quo should remain.

Opponents argue that THC products from hemp aren’t under the purview of any regulatory framework and that is untenable, since any product intended for the market should be regulated in one way or the other.

One factor has become clear as efforts are made to close the so-called “hemp loophole”: the congressional committees that are responsible for formulating hemp policy aren’t the right entities to make laws giving the U.S. Food and Drug Administration (FDA) power over any product. The committees simply oversee agriculture. This explains why, up until now, no regulations have been passed guiding the FDA on how CBD should make its way onto the market or into different consumable products.

Even if the upcoming farm bill was used to provide guidance on THC derived from hemp, it creates more challenges than it solves. For example, would states that have permitted hemp intoxicants renew their laws at least once every five years? Secondly, the Drug Enforcement Administration specifically categorizes synthetic THC as a schedule 1 substance, and not even the reclassification of marijuana would change this classification.

It is becoming increasingly clear that whether THC is derived from marijuana or hemp, it needs to be regulated by a single legal regime. This could mean that manufacturers of hemp-sourced THC products have to adhere to new or existing laws on product testing, advertising, marketing and more. Insisting that the product continue to exist within a “loophole” is counterproductive for the industry in more ways than one. For example, institutional investors are likely to be unwilling to fund such ventures since the segment is open to all manner of legal challenge.

Now may be the time to establish the right regulatory framework for hemp, so that the growth of the industry isn’t left to chance because this risks not only public health but also the very economic interests of those currently engaged in hemp derivative manufacturing.

Regulatory clarity on all forms of THC would help the hemp and cannabis industry, including companies such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), to be more certain about the conditions under which they should expect to operate and make their future plans.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Alternative Products Expo, the Counterculture Festival and Vape Trade Show, Returns to Atlanta this October

Alternative Products Expo (“Alt Pro Expo”), the flagship event series in the global counterculture industry, returns to Georgia at the Atlanta Alt Pro Expo 2024 (“expo”). The upcoming counterculture festival and vape trade show is scheduled for October 10-12, 2024, at the Cobb Galleria Center in Atlanta, Georgia. The expo will showcase an incredible portfolio of must-have products, including vape and hemp products, Delta8, CBD, disposables, kratom, mushrooms, functional beverages, dietary supplements, nootropics, nicotine replacement, energy enhancers, mood changers, herbals, pet products, and other accessories. Given its vast array of vendors, the expo will allow attendees to gain a wealth of invaluable insights, increase market exposure, and build exciting connections.

“Following the success of this year’s Houston event, we are thrilled to be returning to the city of Atlanta, which holds tremendous promise for the counterculture industry. Alternative Products Expo has honed a reputation as the premier platform in this space, and offers unmatchable value in terms of professional networks, educational content, business support to scale your venture, and fine-tuning innovation and distribution strategies. Moreover, we find that the enthusiasm and passion of attendees at our events is palpable and certainly a must-attend for business owners, vendors, growers or anyone else seeking to expand their footprint and knowledge in the region,” said Sebastian Carmona, Director of Partnerships at ZJ Events.

To view the full press release, visit https://cnw.fm/qXEwd

About Alternative Product Expo

Alternative Products Expo, formerly USA CBD Expo, is a production of ZJ Events. Its founders were once exhibitors who, after attending countless trade show events, saw an opportunity to build upon their experience and create an event that combined the best they had seen, with their own notion of what was missing in these business gatherings. By bringing the alternative community together, Alt Pro Expo seeks to provide industry professionals from all corners of the market with an immersive and unique opportunity for networking and business expansion. For more information, please visit https://altproexpo.com/

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study

Lexaria, a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study
The study was made up of three main groups of formulations: DehydraTECH-processed CBD; semaglutide (including “Rybelsus(R)”) and liraglutide
The DehydraTECH-CBD and DehydraTECH-liraglutide both outperformed Rybelsus(R), which was a surprise outcome. DehydraTECH-liraglutide posted a weight reduction of 4.74%, the most significant in the study
For Lexaria, this continued outperformance of DehydraTECH-liraglutide is of particular interest, particularly since many third-party studies have shown semaglutide to be more than twice as effective as liraglutide in promoting weight loss
As the study progresses, Lexaria’s management is optimistic that it will realize positive and ground-breaking results that will demonstrate the superiority and potential of its technology

Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study. This study explores Lexaria’s patented technology, DehydraTECH(TM), and its potential in addressing diabetes and weight loss. More importantly, it looks to establish whether DehdyraTECH processing results in higher brain absorption than non-DehydraTECH arms, with a focus on glucagon-like peptide 1 (“GLP-1”) drugs, liraglutide and semaglutide (https://cnw.fm/iAhxm).

This part of the study was comprised of eight different formulation arms. Arms A through D used different DehydraTECH-CBD compositions, with arms E and F using DehydratTECH-processed Rybelsus, and arms G and H using pure GLP-1 drugs (semaglutide and liraglutide, respectively) processed with DehydraTECH. At the eight-week mark, the liraglutide arm H posted a weight reduction of 4.74%, the most significant weight reduction from the entire study. Equally interesting, two of the DehydraTECH-CBD compositions also led to weight reductions and also outperformed both Rybelsus(R) and pure semaglutide (https://cnw.fm/iAhxm).

For Lexaria, this continued outperformance of DehydraTECH-liraglutide and DehydraTECH-CBD is of particular interest. Lexaria fully owns DehydraTECH-CBD, while liraglutide has become available in generic version. This presents a massive opportunity for Lexaria and its goal of offering a potential treatment option for diabetes and weight loss.

The global diabetes drugs market in 2023 was valued at $79.925 billion. By 2032, it is projected to hit $153.98 billion in value, representing a CAGR of 7% over the forecast period (2024-2032) (https://cnw.fm/fo3Ut). Lexaria looks to carve out a decent market share from this growth with its DehydraTECH technology, primarily by offering a viable oral treatment alternative to what is currently in the market. Its DehydraTECH technology has proven itself many times to improve drug delivery, and it has also done so in its ongoing studies. The company looks to build on this, ultimately offering an oral alternative to diabetes treatment.

As the study progresses, Lexaria’s management is optimistic that it will realize positive and ground-breaking results that will demonstrate the superiority and potential of its technology. They are also confident that results from the study will inch the company closer to carving out a market share in the diabetes and obesity treatment market, even as it continues to create value for its shareholders.

For company information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds Drop in Marijuana Use by Teens, Rise Among Adults

A recent study revealed that marijuana use has been on the rise in the United States, though surprisingly not among young teens. The study, which analyzed the cannabis consumption habits of more than 500,000 people between 2013 and 2022, was published in the latest edition of Drug and Alcohol Dependence Reports. It highlighted that marijuana use saw significant growth among individuals living in households with an annual income exceeding $75,000 and those holding college degrees.

Along with examining usage patterns over the previous 30 days, the study also looked at trends related to household income, age, gender, race, ethnicity and educational background. One unexpected outcome of the research was that cannabis use among teenagers did not increase.

The study grouped all teens aged 12 to 17 years of age together, which may have contributed to the stable numbers. The authors noted that some differences might exist if data on younger and older teens were examined separately. Notably, recent statistics from the Centers for Disease Control and Prevention (CDC) showed a decrease in marijuana use among high school students, dropping from 23% in 2013 to 17% last year.

State-level cannabis legalization could likely be a factor in reducing teen marijuana use. Dispensaries are strictly prohibited from selling to individuals under the age of 21 and typically require ID scanning to verify age, which may reduce illegal purchases compared to liquor stores. Other factors could also be influencing teen behavior, such as the pandemic. According to the authors, there was a notable decline in cannabis use during the pandemic, possibly due to less peer interaction and more parental supervision.

Although marijuana use among teens has stayed steady or declined, the research showed a marked increase in usage among people at higher socioeconomic levels. Cannabis consumption increased by more than threefold among individuals with college degrees and those from higher-income households.

In 2013, only 4% of college-educated people reported using cannabis, but that number grew to nearly 13% by 2022. Similarly, among households earning more than $75,000 annually, marijuana use rose from 6% in 2013 to 13% in 2022.

This shift may be related to changing attitudes toward marijuana due to legalization. Cannabis has become more normalized, especially with endorsements from public figures, including celebrities and athletes. The increasing number of dispensaries in affluent neighborhoods and near universities may also be contributing to this trend.

The authors also suggested that improved access to medical marijuana could explain part of the rise in use among wealthier individuals.

Another notable finding from the study was that marijuana use was most prevalent among non-Hispanic multiracial individuals compared to other racial and ethnic groups, with more than 25% of this group reporting marijuana use in 2022.

This recorded drop in the number of teens using marijuana provides credence to what proponents of legalization indicated that creating a regulated market in which entities such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) are allowed to operate would curb the use of this substance by underaged individuals.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — New Research Shows Cannabis Users Fared Better During COVID-19

According to a recent study, individuals who use cannabis are less likely to die, require a ventilator or suffer from extreme COVID-19 infections. Researchers from New York’s Northwell Health conducted the study, which was just released in the peer-reviewed “Cannabis and Cannabinoid Research” journal.

The study analyzed the National Inpatient Sample Database’s data, focusing on patients admitted with a COVID-19 diagnosis. The patients were divided into two groups: those who used marijuana and those who did not. To ensure fairness, researchers adjusted for various factors, such as race, age, gender and existing health conditions.

Cannabis users had a lower risk of passing away or developing major conditions, including respiratory failure or the need for intubation, according to the study.

According to the data, 28.2% of marijuana users experienced extreme COVID-19 infections, compared to 46.6% of those who did not use marijuana. The death rate among marijuana users was 2.8%, while it was higher at 5.1% for nonusers. Similarly, intubation rates were lower for marijuana users at 7.1%, compared to 9.7% for nonusers. Marijuana users also spent slightly less time in the hospital, with an average stay of 6.4 days versus 7.0 days for those who didn’t use cannabis.

However, Dr. Benjamin Caplan, a medical cannabis expert and author of “The Doctor-Approved Cannabis Handbook,” pointed out some limitations in the study. These include difficulties in properly matching the patients and a lack of specific data, such as the types of products used and the levels of inflammation in patients.

Despite these limitations, Caplan stated that the results were encouraging. He suggested that cannabis could help avoid severe COVID-19 effects by reducing inflammation and immunological reactions.

Further supporting these findings, a 2022 study indicated that certain marijuana compounds might prevent SARS-CoV-2, the virus responsible for COVID-19, from infecting human cells in a lab setting. Researchers discovered that two cannabinoid acids found in hemp, cannabidiolicacid (CBDA) and cannabigerolic acid (CBGA), could bind to the spike protein of the virus. By doing so, these compounds might block the virus from entering cells and causing an infection, opening up potential new treatment and prevention options.

Similarly, a recent Canadian study discovered that by keeping the virus out of cells, lowering oxidative stress and stopping the cytokine storm, cannabinoids may help lessen the severity of COVID-19 infections.

However, not all studies paint a positive picture of marijuana use in relation to COVID-19. Research from the University of Washington, published earlier this year, found that cannabis use was associated with a higher risk of severe COVID-19. Additionally, there is no concrete evidence that smoking cannabis can cure or prevent COVID-19.

As more studies are conducted on the potential therapeutic effects of marijuana on the way people fared during the recent pandemic, there is a possibility that the science could show that the cannabis industry and its many actors, such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), might have in one way or the other supported some people in their struggle against the infection.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com